Sagar Lonial, MD, FACP

Sagar Lonial, MD, and Ellen Marin, PA-C, discuss the impact and key takeaways from their study as well as study limitations and future directions.

Ellen Marin, PA-C, presents the study conclusions and discusses its implications on managing CRS associated with teclistamab with Dr. Lonial.

Study results show that prophylactic tocilizumab reduces CRS incidence and severity in patients receiving teclistamab.

An overview of teclistamab in RRMM and the study methodology of using prophylactic tocilizumab to mitigate CRS associated with teclistamab

Sagar Lonial, MD, and Ellen Marin, PA-C, discuss cytokine release syndrome (CRS) and the strategy to manage CRS in their clinic.

Sagar Lonial, MD, provides an overview of the currently available treatment options in relapsed/refractory multiple myeloma.

Leading experts discuss the evolving landscape of myeloma immunotherapy, highlighting the potential of CAR-T and bispecifics and emphasizing the need for effective management of related toxicities to enhance patient outcomes.

Explore the critical aspects of counseling patients on the expectations and management of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) associated with CAR-T therapy.

Expert panelists review the complex decision-making process between CAR-T and BCMA bispecific therapies in the management of relapsed myeloma, discussing patient-specific factors and relative risks and benefits.

A complex case study in multiple myeloma management, exploring treatment sequencing options for a patient with a long history of disease and multiple lines of therapy.

Gain insight into strategies for monitoring for ICANS and CRS in myeloma treatment, including inpatient and outpatient administration, tocilizumab, dexamethasone, and impact on patient care.

Key opinion leaders share their insight on managing adverse events in myeloma treatment, including dose adjustments and prophylactic strategies to improve outcomes and patient quality of life.

Overview of challenges in managing adverse events associated with bispecific therapy in multiple myeloma, including dysgeusia, skin toxicity, and nail changes patients may experience.

Experts share how the availability of three new bispecific therapies has transformed myeloma patient care, offering a lifeline to those previously without treatment options and showcasing positive responses in various patient populations.

Insight into the latest updates on three approved bispecific therapies in the context of relapsed and refractory multiple myeloma, including teclistamab, talquetamab, and elranatamab, discussing response rates, administration, and side effects.

Dive into a compelling case study showcasing the effective use of talquetamab therapy in the management of relapsed multiple myeloma, discussing responses, side effects, and treatment outcomes.

Explore the potential in earlier use of novel therapy in multiple myeloma, including immunotherapy, bispecifics, and CAR-T therapies, with promising responses and potential paradigm shifts.

Join moderator Sagar Lonial, MD, FACP, and a panel of experts as they discuss recent updates in the management of relapsed and refractory multiple myeloma, exploring impact on clinical practice.

Subject matter experts share strategies for determining treatment selection and duration for patients with transplant-ineligible NDMM.

Subject matter experts share strategies for determining treatment selection and duration for patients with transplant-ineligible NDMM.

Ajay Nooka, MD, MPH, FACP leads a survey of the MAIA study, including a sub-group analysis of the MAIA study in frail patients, as well as findings from the MagnetisMM-6 study.

Jonathan Kaufman, MD describes a second patient case featuring a 76-year-old female diagnosed with transplant-ineligible NDMM.

Defining transplant eligibility, explaining the role of transplant in NDMM, and differentiating between high- and low-risk MM.

Thoughtful discussion centered around recently presented updates to the GRIFFIN, MASTER, and GMMG-CONCEPT studies in NDMM patients.

Nisha Joseph, MD leads an introduction to induction regimen options for patients with transplant-eligible NDMM.

Moderator Sagar Lonial, MD, FACP, and colleagues engage with the first patient case: a 65-year-old female diagnosed with transplant-eligible NDMM.

Closing out their discussion on the management of multiple myeloma, expert panelists highlight unmet needs and look toward future directions in care.

Expert perspectives on the advent of CAR T-cell therapy in relapsed/refractory multiple myeloma, and how its role may integrate with bispecific antibody therapy.

Before closing out their discussion on bispecific antibodies in relapsed/refractory multiple myeloma, key opinion leaders consider optimal sequencing of these agents.

A brief review of non–BCMA-targeted bispecific antibodies under investigation in patients with relapsed/refractory multiple myeloma.